Typically, either a PI in need of assistance or the Drug Development Collaborative (DDC) brings projects to the Core for consideration. The DDC (chaired by Drs. Patricia Steeg and Doug Figg) is a steering committee that provides CCR investigators with assistance in their projects to support pre-clinical development. Projects presented by the DDC are typically in need of re-synthesis or simple medicinal chemistry that will allow the project to move forward in development. Before the Core agrees to undertake the project, the PI presents the project formally to the synthesis team to define the chemistry, synthetic feasibility, cost, time-to-completion, and alternate commercial/ vendor options. Prior to the PI meeting, the synthetic team will have already determined a proposed synthesis and/or explored vendor options. During the PI meeting, a decision is made as to whether or not the Core will undertake the project or recommend an alternate approach. The scope of a particular project is contextual. Some projects are simply synthesis for hire and others are more collaborative in nature and involve co-authoring publications. Joel Schneider actively manages projects. Core group meetings are held in Frederick once a week to discuss progress, troubleshoot chemistry and review analytical data. When needed, Drs. Jay Schneekloth and Martin Schnermann are consulted to develop synthetic strategy. Both PIs have exceptional training in synthetic methodology and natural product synthesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICBC011515-06
Application #
9780252
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Bahr, Julian C; Robey, Robert W; Luchenko, Victoria et al. (2016) Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget 7:69804-69815
Urano, Emiko; Ablan, Sherimay D; Mandt, Rebecca et al. (2016) Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors. Antimicrob Agents Chemother 60:190-7
Smith, Steven J; Pauly, Gary T; Akram, Aamir et al. (2016) Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants. J Acquir Immune Defic Syndr 72:485-91
Smith, Steven J; Pauly, Gary T; Akram, Aamir et al. (2016) Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants. Retrovirology 13:11
Sagher, Ethan; Hernandez, Lidia; Heywood, Callee et al. (2014) The small molecule NSC676914A is cytotoxic and differentially affects NF?B signaling in ovarian cancer cells and HEK293 cells. Cancer Cell Int 14:75
Johnson, Barry C; Pauly, Gary T; Rai, Ganesha et al. (2012) A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants. Retrovirology 9:99